Loading company
Spruce Biosciences, Inc.
SPRB · Nasdaq · ·
Next earnings: November 9, 2026
$47.53-0.4%Sep 29 close
- 1M
- -21.8%
- 6M
- -18.8%
- 1Y
- +431.0%
- 5Y
- +690.8%
SPRB · Nasdaq · ·
Next earnings: November 9, 2026
$47.53-0.4%Sep 29 close
Spruce Biosciences, Inc. is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2025 | 3 months toDec 31, 2024 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $697K | -100.00% |
| Profit | -$16.2M | -$2.1M | -685.15% |
| Profit per share | -$6.68 | -$0.23 | -2,804.35% |
| Free Cash Flow | -$22.3M | -$20.7M | -7.63% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The second quarter was a period of significant execution as we advanced TA-ERT toward our planned BLA submission in the fourth quarter, which would be a transformative milestone for Spruce and for the children and families living with MPS IIIB,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. Spruce’s lead product candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is in late-stage development for the treatment of mucopolysaccharidoses type IIIB (MPS IIIB), or Sanfilippo Syndrome Type B, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. To learn more, visit www.sprucebio.com and follow us on X , LinkedIn , Facebook and YouTube .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Spruce Biosciences, Inc.’s Item 2.02 8-K filed August 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Spruce Biosciences, Inc. has no earnings call transcript available.